1 h after injection, 90–100% of the CD8+ T cells in the blood, spleen, and tumor tissue were bound by DiD-labeled CD8a-targeting nanoparticles, as determined by flow cytometry (Fig. 2d, upper panel). This evidence concerns the gene CD8A and neoplasm.